Esperion Therapeutics (ESPR) News Today → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free ESPR Stock Alerts $1.90 -0.09 (-4.52%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEsperion to Report First Quarter 2024 Financial Results on May 7finance.yahoo.com - April 23 at 3:46 PM11 Best Low Price Pharma Stocks To Invest Infinance.yahoo.com - April 21 at 12:28 PMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of "Hold" from Analystsamericanbankingnews.com - April 20 at 2:50 AMNeedham & Company LLC Reaffirms "Buy" Rating for Esperion Therapeutics (NASDAQ:ESPR)marketbeat.com - April 10 at 8:17 AMEsperion Therapeutics (NASDAQ:ESPR) Trading Down 3.1%marketbeat.com - April 8 at 2:28 PMEsperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groupsmsn.com - April 8 at 10:34 AMEsperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesityglobenewswire.com - April 7 at 2:45 PMZacks Research Weighs in on Esperion Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ESPR)marketbeat.com - April 5 at 8:36 AMEsperion Therapeutics (NASDAQ:ESPR) Reaches New 12-Month High at $3.40marketbeat.com - April 4 at 10:46 AMFY2025 EPS Estimates for Esperion Therapeutics, Inc. Cut by Zacks Research (NASDAQ:ESPR)marketbeat.com - April 4 at 9:44 AMSignet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesdaymsn.com - April 3 at 12:50 PMEsperion Therapeutics (NASDAQ:ESPR) Trading 5.2% Higher marketbeat.com - April 1 at 4:50 PMEsperion to Ring Nasdaq Opening Bell Today, April 1, 2024globenewswire.com - April 1 at 8:00 AMEsperion Therapeutics (NASDAQ:ESPR) Shares Gap Up to $2.70marketbeat.com - March 27 at 12:22 PMHC Wainwright Equities Analysts Decrease Earnings Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR)marketbeat.com - March 27 at 6:34 AMEsperion Therapeutics (NASDAQ:ESPR) Sees Unusually-High Trading Volumemarketbeat.com - March 26 at 12:37 PMEsperion to Participate in 23rd Annual Needham Virtual Healthcare Conferencefinance.yahoo.com - March 26 at 10:13 AMWhy Is Heart Disease-Focused Esperion Therapeutics Stock Trading Higher On Monday?msn.com - March 26 at 12:10 AMEsperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24globenewswire.com - March 25 at 4:00 PMEsperion Therapeutics' (ESPR) Buy Rating Reaffirmed at HC Wainwrightmarketbeat.com - March 25 at 1:09 PMEsperion Therapeutics Target of Unusually High Options Trading (NASDAQ:ESPR)marketbeat.com - March 25 at 11:53 AMEsperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market Sessionmsn.com - March 25 at 6:47 AMEsperion Therapeutics Inc.money.usnews.com - March 23 at 8:07 AMU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Usefinance.yahoo.com - March 22 at 9:56 PMU.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Usebusinesswire.com - March 22 at 6:26 PMU.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Useglobenewswire.com - March 22 at 3:10 PMEsperion Therapeutics Gets CHMP Positive Opinion for Cholesterol Medicationsmarketwatch.com - March 22 at 11:55 AMCHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Eventsglobenewswire.com - March 22 at 11:04 AMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Expected to Post Q1 2024 Earnings of ($0.38) Per Sharemarketbeat.com - March 21 at 8:03 AMZacks Research Comments on Esperion Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:ESPR)marketbeat.com - March 20 at 7:19 AMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Updatemarketbeat.com - March 19 at 10:54 PMTerns to report Phase 1 data on GLP-1 drug in 2H 2024msn.com - March 14 at 8:52 PMGSA Capital Partners LLP Has $1.09 Million Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)marketbeat.com - March 10 at 7:48 AM11 Best Small Cap Pharma Stocks to Invest Infinance.yahoo.com - March 4 at 9:04 PMEsperion Therapeutics, Inc. Expected to Earn Q1 2024 Earnings of ($0.24) Per Share (NASDAQ:ESPR)marketbeat.com - March 2 at 2:29 AMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of "Hold" by Analystsmarketbeat.com - March 1 at 1:26 AMA Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeuticsseekingalpha.com - February 28 at 7:10 PMEsperion Therapeutics (NASDAQ:ESPR) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPSmarketbeat.com - February 28 at 10:27 AMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 28 at 9:09 AMQ4 2023 Esperion Therapeutics Inc Earnings Callfinance.yahoo.com - February 28 at 12:41 AMEsperion Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - February 27 at 10:42 AMEsperion Therapeutics, Inc.: Esperion Reports Fourth Quarter and Full Year 2023 Financial Resultsfinanznachrichten.de - February 27 at 9:40 AMEsperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023finance.yahoo.com - February 27 at 9:40 AMEsperion Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - February 27 at 6:00 AM12 Best Medical Stocks to Buy Under $10finance.yahoo.com - February 27 at 4:40 AMEarnings Preview: Esperion Therapeuticsbenzinga.com - February 26 at 10:39 PMEsperion Therapeutics, Inc.edition.cnn.com - February 26 at 5:39 PMWhat Wall Street expects from Esperion Therapeutics's earningsmarkets.businessinsider.com - February 26 at 12:39 PMEsperion Therapeutics Q4 2023 Earnings Previewmsn.com - February 26 at 12:39 PMESPR Jan 2026 4.000 callca.finance.yahoo.com - February 19 at 1:42 AM Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy ESPR Media Mentions By Week ESPR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESPR News Sentiment▼1.190.33▲Average Medical News Sentiment ESPR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESPR Articles This Week▼32▲ESPR Articles Average Week Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alto Neuroscience News Today ADC Therapeutics News Today FibroBiologics News Today Atai Life Sciences News Today Nature's Sunshine Products News Today Amarin News Today Organogenesis News Today Rani Therapeutics News Today UroGen Pharma News Today Precigen News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESPR) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
